A brief run up is not a reason to sell. Stiff-em offered no pertinent information. Korlym has application for treatment of breast cancer and treatment psychotic depression. The depression application is currently nearing the end of phase 3 trials. This stock will be a 5-10 bagger or more. Search smallcapnetwork for better information.
They're shaking the trees to accumulate shares. When Korllym is approved for psychotic depression, Corcept will be a 5 to 10 bagger. That's why Corcept has run up in recent weeks. Don't let the schemers take your shares. Have some patience.